Clinical trial • Phase I • Other
Erlotinib for Cancer
Phase I trial of Erlotinib for Cancer. 87 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Cancer
- Trial Stage
- Phase I
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 07-11-2024
- First CTIS Authorization Date
- 11-12-2024
Trial design
Phase I trial across 1 site in Austria.
- Target Sample Size
- 87
Eligibility
Recruits 87 No vulnerable population selected..
- Vulnerable Population
- No vulnerable population selected.
Recruitment
- Planned Sample Size
- 87
- Recruitment Window Months
- 167
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 87
Austria
- Earliest CTIS Part Ii Submission Date
- 19-11-2024
- Latest Decision Or Authorization Date
- 11-12-2024
- Processing Time Days
- 22
- Number Of Sites
- 1
- Number Of Participants
- 87
Sites
- Site Name
- Medical University Of Vienna
- Department Name
- Department of Clinical Pharmacology
- Principal Investigator Name
- Markus Zeitlinger
- Principal Investigator Email
- markus.zeitlinger@meduniwien.ac.at
- Contact Person Name
- Markus Zeitlinger
- Contact Person Email
- markus.zeitlinger@meduniwien.ac.at
Sponsor
Primary sponsor
- Full Name
- Medical University Of Vienna
- Organisation Type
- Educational Institution
- Country Of Registered Address
- Austria
Investigational products
- Investigational Product Name
- Erlotinib
- Active Substance
- Erlotinib
- Modality
- Small molecule
Related trials
Other published trials that may interest you.